Adam Chazan This is Me

Education

 View all 77 references Web References

1. 1. Wisconsin Biotechnology & Medical Device Association : Third Wave Technologies

   www.wisbiomed.org/biotech_news - [Cached]

   Published on: 7/25/2007   Last Visited: 12/26/2007

   Research analyst Adam Chazan of Pacific Growth Equities in San Francisco applauded the move, saying it's an area "which we believe will become the cornerstone of personalized medicine."
   
   Third Wave is also developing products to screen for tuberculosis and for respiratory viruses that could include influenza.
   
   In a research note issued Wednesday, Chazan lowered his forecast for 2005 to a 40-cent-per-share net loss with $30.2 million in sales. But he retained his "over weight" rating for Third Wave, meaning the stock's total return is expected to exceed the industry average.
   
   "In our view, (Third Wave) remains an attractive play on the growing molecular diagnostics market," Chazan wrote.
   ...
   Analysts Adam Chazan and Zarak Khurshid, of Pacific Growth Equities in San Francisco, said the first-quarter results were "disappointing," and fell below their projections of $8.6 million in revenue and a 5 cent per share net loss.
   
   In a research note Thursday, Chazan and Khurshid said they expect Third Wave to show sales of $32.5 million for the year with a net loss of 32 cents a share, but continued their "overweight" rating, meaning the stock's return is expected to be better than the industry average.
   ...
   "In our view, Third Wave Technologies is becoming a more focused molecular diagnostics story with significant growth opportunities from current and future products and geographies," wrote analyst Adam Chazan of Pacific Growth Equities in San Francisco in a research note Wednesday.
   ...
   "We continue to like Third Wave Technologies (Nasdaq: TWTI) and feel its transformation into a molecular diagnostics company is well underway," said the report by senior life sciences analyst Adam Chazan of Pacific Growth Equities in San Francisco on Tuesday. Chazan gives the shares an "over weight" rating, which means the stock's total return is expected to exceed the industry average over the next 12 to 18 months.
   ...
   Analyst Chazan projected shares could trade at $6.50 to $8 in the next 12 to 18 months.

2. 2. Pacific Growth Equities, LLC

   www.pacgrow.com/research/healt - [Cached]

   Published on: 1/10/2006   Last Visited: 1/10/2006

   Adam Chazan, M.S.
   ...
   Adam Chazan, M.S.
   
   Adam comes to Pacific Growth Equities from Merrill Lynch where he was an equity research analyst following companies in the life sciences tools, genomics and drug discovery sectors. Prior to Merrill, Adam was in the healthcare equity research groups of ING Barings LLC and William Blair & Company. Prior to joining the sell side, Adam was with Donaldson Capital Management in its Bios Equity Fund.
   
   Areas of Specialty: Life Sciences Tools & Diagnostics
   
   Education: Adam received his BS from Cornell University and his MS, Biotechnology from Northwestern University.

3. 3. Investor's Business Daily stock analysis and business news

   www.investors.com/editorial/IB - [Cached]

   Published on: 9/16/2005   Last Visited: 9/19/2005

   Techne's sales strategy also carries a competitive risk, says analyst Adam Chazan of Pacific Growth Equities.
   
   "Techne has a great reputation and serves as the one-stop shop for cytokine and cell signaling reagents, but they do face competition from larger companies that offer both catalog sales and direct sales reps," he said.
   ...
   Chazan is waiting to see how Techne will handle these buyouts.
   
   "How will they integrate the businesses and develop their new business opportunities in the next 12 to 18 months?" he said.